Sparsentan approved to treat adult patients with primary immunoglobulin A nephropathy (IgAN)

HM Government

Twitter

Facebook

email

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy (IgAN).

Follow this news feed:

Greens welcome £1bn in funding for buses but challenge scrapping £2 fare cap and call for bus priority measures Guidance: Tree health pilot scheme

Leave a Reply Cancel reply